Clinical Trial Update: A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 open-label interventional study evaluating intravenous efanesoctocog alfa (BIVV001) in severe hemophilia A has completed with results posted in May 2023…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Efanesoctocog alfa (efanesoctocog alfa)

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Factor VIII Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2023-05-24